Vendor-published case materials describe a multi-year, multi-country MMM program with reported financial benefits and expansion across markets. Independent coverage of the program references substantial incremental revenue claims and highlights that MMM performance is more reliable in stable market conditions and less predictable during major macro shocks (for example, the COVID-19 pandemic).
Critical evaluation:
- Positive signals: multi-year adoption and cross-market deployment suggest operationalisation beyond a single study.
- Caveat: financial impact metrics depend on modelling assumptions, validation approaches, and the definition of incremental outcomes. Buyers should request methodological appendices, validation results, and access to reference customers.